Kakoli Das

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2869172/publications.pdf Version: 2024-02-01



KAKOLI DAS

#	Article	IF	CITATIONS
1	<i>HNF4α</i> pathway mapping identifies wild-type <i>IDH1</i> as a targetable metabolic node in gastric cancer. Gut, 2020, 69, 231-242.	6.1	27
2	An LCM-based genomic analysis of SPEM, Gastric Cancer and Pyloric Gland Adenoma in an Asian cohort. Modern Pathology, 2020, 33, 2075-2086.	2.9	6
3	A functional network of gastric-cancer-associated splicing events controlled by dysregulated splicing factors. NAR Genomics and Bioinformatics, 2020, 2, Iqaa013.	1.5	5
4	Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. Journal of Clinical Investigation, 2020, 130, 3005-3020.	3.9	12
5	New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gastric Cancer, 2019, 22, 77-90.	2.7	41
6	KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status. Pathology and Oncology Research, 2019, 25, 333-340.	0.9	29
7	Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. Cancer Cell, 2018, 33, 137-150.e5.	7.7	175
8	Frequent Coamplification of Receptor Tyrosine Kinase and Downstream Signaling Genes in Japanese Primary Gastric Cancer and Conversion in Matched Lymph Node Metastasis. Annals of Surgery, 2018, 267, 114-121.	2.1	15
9	Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial. Cancer Letters, 2018, 412, 208-215.	3.2	10
10	Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β. Molecular Cancer Therapeutics, 2018, 17, 232-242.	1.9	42
11	The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. International Journal of Molecular Sciences, 2018, 19, 2079.	1.8	26
12	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Scientific Reports, 2016, 6, 19552.	1.6	26
13	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. ESMO Open, 2016, 1, e000009.	2.0	16
14	<i>SETD2</i> histone modifier loss in aggressive GI stromal tumours. Gut, 2016, 65, 1960-1972.	6.1	49
15	Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. Cancer Letters, 2014, 353, 167-175.	3.2	50
16	Using Genomic Biomarkers to Predict Patient Prognosis and Treatment Response in Gastric Cancer. , 2013, , 105-136.		1
17	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut, 2012, 61, 673-684.	6.1	562
18	Genomic Loss of <i>miR-486</i> Regulates Tumor Progression and the <i>OLFM4</i> Antiapoptotic Factor in Gastric Cancer. Clinical Cancer Research, 2011, 17, 2657-2667.	3.2	200

#	Article	IF	CITATIONS
19	Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocrine-Related Cancer, 2010, 17, 757-770.	1.6	27
20	Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. European Journal of Cancer, 2009, 45, 2239-2248.	1.3	44
21	Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer. Cancer Letters, 2008, 268, 340-347.	3.2	16
22	Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 317-321.	0.8	16